Genentech, Inc. announced recently that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months, in patients with macular edema due to branch retinal vein occlusion.
Caroline Tate of Charlotte can see her grandchildrens' faces, and enjoys the gift of vision that Lucentis has given her. In 2005 she was diagnosed to have macular degeneration. Read the success story of a brave woman who was determined to fight it out.
National Institute For Clinical Excellence (NICE) has launched a special scheme which will help people suffering from macular degeneration to avail Novartis AG's, pricey eye drug Lucentis through cost effective scheme.
The Macular degeneration is the type of eye disease that develops in the older people. It is one of the major causes of vision loss in countries like the USA, especially among the age group of 65 and above. According to the Archives of Ophthalmology, nearly 1.75 million people were identified with the age related macular degeneration. And as the older people constitute a large portion of the population, the AMD, age related Macular Degeneration, and related vision loss is a major growing problem in the USA.
The macular degeneration takes place when blood vessels grow under retina, then leak and bleed. This in result can cause a blinding scare. As the macular primarily is affected in the AMD, the central vision loss may also suffer. The macular degeneration can be of two types, wet and dry.
